The latest medical insurance price of dasatinib in 2026

Dasatinib (Dasatinib) is a relatively mature second-generation tyrosine kinase inhibitor used in the field of hematological tumors. It is mainly used for the long-term treatment of chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and other diseases. Currently, dasatinib has been officially approved for marketing in mainland China and has been included in the National Reimbursement Directory, which is of great significance to patients' long-term drug accessibility. However, it should be noted that medical insurance reimbursement is usually limited to patients who meet the indications and medication conditions, and not all users can automatically enjoy reimbursement benefits.

Based on current market information, the common dosage forms of dasatinib in China include 50 mg × 60 tablets and 20 mg × 60 tablets. Taking the winning bid price after medical insurance negotiation as a reference, the price of a single box is approximately RMB 10,000. The specific price will vary depending on regional procurement policies, hospital pricing and reimbursement ratios. For patients who need long-term or even lifelong medication, the medical insurance policy has significantly reduced the actual economic burden to a certain extent, making this targeted treatment program more sustainable.

In the actual medication process, the final cost borne by the patient not only depends on the drug price, but is also closely related to the type of personal medical insurance, reimbursement ratio and whether the reimbursement conditions are met. With the support of outpatient chronic disease or special disease management policies, the actual out-of-pocket amount for some patients may be significantly lower than the listed price. This is also an important reason why the number of people using dasatinib has gradually expanded in recent years. Judging from overseas drug use experience, dasatinib has long been regarded as a chronic disease management drug. The gradual improvement of domestic medical insurance coverage is basically consistent with international treatment concepts.

It should be reminded that medical insurance prices are not fixed. With policy adjustments and subsequent negotiations, drug prices may change in stages. Therefore, it is best for patients to obtain the latest information from the hospital or local health insurance department before starting or adjusting their treatment plan.

Reference materials:https://go.drugbank.com/drugs/DB01254